close
Add to watchlist
Achillion Pharmaceuticals Inc (ACHN)
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C and HIV infection; and the development of antibacterials for the treatment of resistant bacterial infections. Its products include ACH-1095, a NS4A antagonist that is in late-stage preclinical studies for the treatment of chronic hepatitis C infections; ACH-1625, a protease inhibitor, which is in the preparation for phase I initiation for the treatment of chronic hepatitis C infections; ACH-702, a preclinical candidate that is in preclinical stage with potency against a spectrum of bacterial pathogens, including methicillin-resistant staphylococcus aureus for drug resistant bacterial infections; and Elvucitabine, which completed phase II studies for the treatment of HIV infection. The company has a collaboration arrangement with Gilead Sciences, Inc. to develop and commercialize compounds for use in treating hepatitis C infection, which inhibit viral replication through a mechanism of action. The company was founded in 1998 and is based in New Haven, Connecticut.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 10.78 |
| Volume | 691624 |
| Volume Avg | (mio) 1.63 |
| 52 Week High | 12.95 |
| 52 Week Low | 3.81 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -0.69 |
| EPS change Q/Q | -54.55% |
| EPS change Q/Q Yr ago | -6.25% |
| EPS change Q/Q next Q est | 0% |
| EPS change Y/Y | -46.67% |
| REV change Q/Q | -95% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | -0.17 |
| EPS next Y est | -0.70 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |